Tech Company Financing Transactions

SalioGen Therapeutics Funding Round

On 1/8/2022, SalioGen Therapeutics announced $115 million in Series B funding from Epiq Capital, GordonMD Global Investments and Cystic Fibrosis Foundation.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

245 First St. 18th Floor
Cambridge, MA 02142
USA

Phone

(857) 990-2200

Website

www.saliogen.com

Email Address

[email protected]

Overview

Our mission is to transform the treatment paradigm for patients with inherited disorders by developing durable, broadly applicable, life-altering therapies grounded in innovative and rigorous science. By advancing a new category of genetic medicine, at SalioGen, we aspire to treat all inherited disorders, rare or common.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Ray Tabibiazar

        

President

Joseph Higgins

        

VP - Bus. Development

Sung Yu

        

VP - Engineering

Nancy Craig

        

VP - Operations

Sandeep Nema

        

Browse more venture capital transactions:

Prev: 1/8/2022: Brankas venture capital transaction
Next: 1/8/2022: Goldfinch venture capital transaction

Share this article

About Our Venture Capital Transactions Database

Our team works diligently to record every notable VC transaction. VC investment data records on this site are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary